Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Eli Lilly stock has crushed the broader markets in the past 10 years. But should you buy LLY at current levels, given its lofty valuation?

Barchart

Drug used in diabetes treatment Mounjaro helped dieters shed 60 pounds, study finds

A new study finds that the medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight

The Independent UK

US nutrition panel’s ties to top food giants revealed in new report

Transparency group US Right to Know finds members linked to Nestlé, Coca-Cola and others, raising conflict-of-interest questions

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's What $1,000 Invested in Eli Lilly 10 Years Ago Would Be Worth Now

Eli Lilly stock has surged over 1,200% in the last 10 years. Here's why I remain bullish on this blue-chip healthcare stock right now.

Barchart

Mounjaro: type 2 diabetes drug more effective than Ozempic to launch in the UK — here’s what you need to know

A new drug to treat type 2 diabetes has been approved for use) in the UK. Tirzepatide (sold under the brand name Mounjaro) could be available for prescription by early 2024 – subject to availability.

The Conversation

Wegovy: the slimming drug that keeps Denmark’s economy growing

Novo Nordisk, the maker of the blockbuster obesity injection, has singlehandedly saved the country from recession

The Guardian - UK

Another weight loss jab approved for NHS use

The once-weekly jab was hailed as a ‘much-needed addition to other available treatments’

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Weight loss jab recommended to treat type 2 diabetes

The once-weekly jab was hailed as a ‘much-needed addition to other available treatments’

The Independent UK

Chart of the Day: Eli Lilly (LLY) Edges to New Record High

The Barchart Chart of the Day belongs to Eli Lilly (LLY) . I found the stock by using Barchart.com to find the "Barchart New Highs" page, and then I clicked on pull-down to select stocks with new 52-week highs. I then viewed the stocks on the list with the FlipCharts...

Barchart

A trial to test a new path for preventing Alzheimer’s

Alzheimer research made a breakthrough last month when Eli Lilly's drug donanemab slowed cognitive decline in 47% of those taking it. It follows two other drugs, lecanemab and aducanumab, that target amyloid protein buildup in the brain. However, these drugs can cause fatal brain bleeding and seizures. Oxidative stress hypothesis…

The Hindu

Insulin Patients Can Find Discounts With Amazon's New Automated Coupon System

Amazon Pharmacy will automatically apply manufacturer-sponsored coupons for 15-plus products.

Kiplinger

Tesla Hires New Exec To Lead Giga Nevada's Massive $3.6B Expansion

Before joining Tesla in July, Michael Hildebrand was executive director of projects at Eli Lilly, where he spent the previous 19 years of his career.

InsideEVs

Stock Market Today: Stocks Drop on Troubling China Data, Bank Ratings Worries

The main benchmarks fell Tuesday, but healthcare stocks outperformed as Eli Lilly and Novo Nordisk surged.

Kiplinger

Soaring sales of diabetes drug Mounjaro, often used for weight loss, sends Eli Lilly to new heights

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

The Conversation

The obesity epidemic is fuelled by biology, not lack of willpower

Since the time a human first used a tool to make life easier, increased weight has been inevitable.

The Conversation

Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

Trial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.

StockNews.com

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

New drug found to slow Alzheimer’s hailed as turning point

Donanemab has been found to slow down the disease in a clinical trial.

The Independent UK

Everything we know about breakthrough Alzheimer’s drug Donanemab

Alzheimer’s disease is the most common cause of dementia in the UK

Evening Standard

Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

The Guardian - UK

What impact will Alzheimer’s drug donanemab have?

While it is not a cure, proof that drugs can alter course of disease is regarded as significant triumph

The Guardian - UK

Experts urge health regulators to approve ‘turning point’ dementia drugs

Exclusive: As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

Fortune

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

The Guardian - UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

1 … 21 22 23 24

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.